An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

20203,455 citationsJournal Articlegreen Open Access

Authors

Lisa A. Jackson · University of Maryland, Baltimore

Evan J. Anderson · University of Maryland, Baltimore

Nadine Rouphael · University of Maryland, Baltimore

Paul C. Roberts · University of Maryland, Baltimore

Mamodikoe Makhene · University of Maryland, Baltimore

Rhea N. Coler · University of Maryland, Baltimore

Michele Paine McCullough

Abstract

The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 ClinicalTrials.gov number, NCT04283461).

Topics & Keywords

SARS-CoV-2 and COVID-19 Research RNA Interference and Gene Delivery Viral gastroenteritis research and epidemiology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 20, pp. 1920-1931

DOI: 10.1056/nejmoa2022483

Field-Weighted Citation Impact: 76.56